



materialise
innovators you can count on

Q3 2026 Financial Results

Conference call | October 28, 2026
www.materialise.com | NASDAQ & Euronext: MTL

Safe Harbor Summary

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations, plans, objectives, strategies and prospects, both financial and business, including statements concerning, among other things, our estimates for revenue, Adjusted EBITDA, Adjusted EBIT, our results of operations, cash needs, capital expenditures, expenses, financial condition, liquidity, prospects, growth and strategies (including how our business, results of operations and financial condition could be impacted by the current armed geopolitical conflicts around the world and governmental responses thereto, inflation, increased labor, energy and materials costs), policy changes resulting from the U.S. presidential administration, changes in tariffs and trade restrictions, and the trends and competition that may affect the markets, industry or us. Such statements are subject to known and unknown uncertainties and risks. When used in this presentation, the words “estimate,” “expect,” “anticipate,” “project,” “plan,” “intend,” “believe,” “forecast,” “will,” “may,” “could,” “might,” “aim,” “should,” and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this presentation. These expectations, beliefs and projections are expressed in good faith and the company believes there is a reasonable basis for them. However, the company cannot offer any assurance that our expectations, beliefs and projections will actually be achieved. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. All of the forward-looking statements are subject to risks and uncertainties that may cause the company's actual results to differ materially from our expectations, including risk factors described in the company's annual report on Form 20-F filed with the U.S. Securities and Exchange Commission. There are a number of risks and uncertainties that could cause the company's actual results to differ materially from the forward-looking statements contained in this presentation.

This presentation includes non-IFRS financial measures, including EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA. These measures are supplemental measures of financial performance that are not required by, or presented in accordance with, international financial reporting standards (“IFRS”). Please refer to the Appendix of this presentation for a reconciliation of such non-IFRS financial measures to the most directly comparable financial measures prepared in accordance with IFRS.

Agenda

- Q3 2026 Business Highlights
- Q3 2026 Financial Highlights
- Q3 2026 Financial Results
- 2026 Financial Guidance
- Q&A

Brigitte de Vet-Veithen
CEO




Koen Berges
CFO



Q3 2026 Business Update

Medtech – *Scaling Access to Personalized Care*

- Signing partnership with Superhumans Center to support reconstructive cranio-maxillofacial surgery in Ukraine and launching innovations to support healthcare efficiencies in CMF
- Expanding cardiac planning software with Valve-in-Valve capabilities
- Expanding Soft Tissue surgery planning software with dedicated workflow for Liver resection



Software – *Growing Our Software Ecosystem*

- Commercial momentum for our CO-AM platform
- Expanding security capabilities through the integration of CO-AM Brix and Identify3D
- Gearing up for Formnext, the world's leading additive manufacturing trade show



Manufacturing – *Delivering Certified Additive Manufacturing Solutions*


- Continued growth in series manufacturing, driven by aerospace, semiconductor and defense
- Expanding our metal additive manufacturing capabilities
- Strong uptake of Phits Dynaprint orthotics in our Motion business



Q3 2026 – Financial Highlights


- **Revenue** of 67.7 mEUR, representing an increase of 2.1% from Q3 2025
- **Gross Profit** of 39.0 mEUR, representing 57.7% of revenue
- **Adjusted EBIT** of 2.5 mEUR, representing 3.7% of revenue
- **Net profit** of 1.4 mEUR, representing 2 EUR-ct. per share
- **Net Cash** position of 82.5 mEUR, representing an increase of 11.7 mEUR from year-end 2025, while YTD 7.5 mEUR was invested in share buybacks

Consolidated Revenue





[Data in mEUR unless notes otherwise. All numbers and percentages rounded]

Q3 2026 Revenue by Segment



- Revenue of 67.7 mEUR increases by 2.1% compared to 2025. Adjusted for recent divestments revenue grows by 4.9% year-over-year
- 10% revenue growth in our Medical segment while Aerospace & Defense focus areas drive growth in series manufacturing
- 45.2 mEUR of deferred revenue from software licenses and maintenance carried on our balance sheet at the end of Q3 2026

Consolidated Adjusted EBIT & EBITDA




[Data in kEUR unless notes otherwise. All numbers and percentages rounded]


- Q3 2026 Adjusted EBIT and Adjusted EBITDA both end lower compared to Q3 2025
- Higher gross profit is offset by increased R&D investments and one-off indirect costs

Q3 2026

Medical Segment




[Data in kEUR unless notes otherwise. All numbers and percentages rounded]




- Q3 2026 revenue increased 10% to 36.5 mEUR
 - Revenue from medical devices & services increased 10%
 - Revenue from medical software increased 10%
- Q3 2026 Adjusted EBITDA landed at 10.0 mEUR, representing an Adjusted EBITDA margin of 27%

Software Segment




[Data in kEUR unless notes otherwise. All numbers and percentages rounded]




- Q3 2026 revenue decreased 4% to 9.9 mEUR
- Recurring revenue represented 84% in Q3 2026
- Q3 2026 Adjusted EBITDA landed at 1.5 mEUR, representing an Adjusted EBITDA margin of 15%

Manufacturing Segment



[Data in kEUR unless notes otherwise. All numbers and percentages rounded]




- Q3 2026 revenue decreased by 6% to 21.3 mEUR compared to Q3 2025. Adjusted for recent divestments revenue grows by +1%
- Growth in strategic focus segments in series manufacturing is offset by lower prototyping demand compared to PY
- Q3 2026 Adjusted EBITDA improved to (0.3) mEUR, representing an Adjusted EBITDA margin of (1)%


Income Statement Highlights

	Q3 2026	Q3 2025
Revenue	67,670	66,259
Cost of sales	(28,635)	(28,608)
Gross profit	39,035	37,651
Research & development expenses	(12,805)	(11,439)
Sales & marketing expenses	(15,561)	(14,847)
General & administrative expenses	(10,464)	(9,733)
Other income/(expenses), net	1,137	890
Operating profit/(loss)	1,343	2,522
Financial income/(expenses), net	160	(121)
Taxes	(120)	(553)
Net profit/(loss)	1,383	1,848
Diluted EPS (in EUR)	0.02	0.03
(Diluted) weighted average shares (thousands)	58,061	59,067

Gross profit margin (in %)



Diluted EPS (in EUR)




[Data in kEUR unless noted otherwise. All numbers and percentages rounded]


Other Financial Highlights

Balance Sheet items	30/09/26	31/12/25
Cash and equivalents	153,529	133,918
Borrowings	71,056	63,113
Net Cash	82,473	70,805
Trade receivables	48,783	54,938
Inventories	17,418	14,904
Trade payables	20,927	20,125
Deferred income	59,159	60,867
Equity	255,809	255,482
Total balance sheet	429,576	420,646

Cash flow from operations



Capital expenditures (cash impact)



[Data in kEUR unless noted otherwise. All numbers and percentages rounded]

2026 Financial Guidance Update

Maintaining prior guidance on revenue and Adjusted EBIT

- Expect 2026 **consolidated revenue** within 273 - 283 mEUR range
- Expect 2026 **consolidated Adjusted EBIT** within 12 - 14 mEUR range



Adjusted EBIT/EBITDA Reconciliation

	Q3	
[Data in kEUR unless noted otherwise. All numbers and percentages rounded]	2026	2025
Net profit/(loss)	1,383	1,848
Income taxes	120	553
Financial expenses	1,128	582
Financial income	(1,289)	(460)
EBIT	1,343	2,522
Depreciation & amortization	5,561	5,509
EBITDA	6,904	8,031
Share-based compensation expense	360	74
Restructuring and corporate initiatives	577	322
Impairments	184	-
Divestitures-related expenses	22	-
Adjusted EBITDA	8,046	8,428
Depreciation & amortization	(5,561)	(5,509)
Adjusted EBIT	2,485	2,918

Thank You

Contact:
Investor Relations Materialise
investors@materialise.com

